Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.40 |
| ▸ | FDPS | P14324 | 9/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL4096363 | 1.00 | LMNA (0.62) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| Hexane SCHEMBL2888898 | 1.00 | LMNA (0.62) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL29801733 | 0.95 | LMNA (0.68) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2345608 | 0.95 | LMNA (0.68) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL30646406 | 0.95 | LMNA (0.68) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2346119 | 0.95 | LMNA (0.68) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL14208157 | 0.95 | LMNA (0.52) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL6354364 | 0.95 | LMNA (0.52) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2344964 | 0.95 | LMNA (0.52) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL2350132 | 0.93 | LMNA (0.50) | LMNAALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946476-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2352721-B1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | UCB PHARMA GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2352721-A1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB Pharma GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052011-A1 | NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA, S.A. (BE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263899-A1 | Novel Process for the Preparation of Amino Acid Derivatives | BCAT2, DNPEP, NPEPPS | LMNA 1165/4885ALDH1A1 2432/4885TSHR 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.